Do no harm: a roadmap for responsible machine learning for health care

Interest in machine-learning applications within medicine has been growing, but few studies have progressed to deployment in patient care. We present a framework, context and ultimately guidelines for accelerating the translation of machine-learning-based interventions in health care. To be successful, translation will require a team of engaged stakeholders and a systematic process from beginning (problem

Read More


FDA Approves JAK Inhibitor for Moderate to Severe Rheumatoid Arthritis

The FDA approved upadacitinib (Rinvoq, AbbVie), a 15-mg, once-daily oral Janus kinase inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The approval is supported by data from the SELECT program, one of the largest registrational phase 3 clinical programs

Read More


$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain. About 20% of breast cancers are HER2-positive, and nearly half of women with this type of breast cancer develop brain

Read More


A deluge of data: A pledge to the democratization of healthcare

AI and machine learning can transform data from health records — “real world data” — into “real world evidence” that will bolster the medical community’s collective knowledge exponentially. Yet, clinical decision support platforms are the only way all this added practice-based knowledge can actually be used to improve overall care. Since Stanford Medicine’s 2018 Health Trends

Read More


Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

 Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the news announced today by Atelerix that it has been awarded a grant of £267,000 from Innovate UK. The grant will be used to develop gel stabilisation technologies, developed by Atelerix, with the first objective of extending the

Read More